News Why relying on AI outcome models may not be a good idea The use of AI outcome prediction models (OPMs) in medicine is on the rise, but a new paper has warned widespread use could lead to patient harm.
Digital Alongside diagnosis: AI’s role in shaping health transformat... Humans are about to go hybrid – in fact, our race is undergoing its own digital transformation.
R&D Defining innovation: The battle for clarity, access, and sta... The pharmaceutical industry often claims its medicines as highly innovative and expects to be compensated accordingly.
News Chiesi signs $1.9bn deal to buy KalVista and its HAE drug Chiesi has boosted its rare disease business with an agreement to buy KalVista and Ekterly, its oral drug for treating attacks in rare disease HAE.
Sales & Marketing Sponsored Using AI-driven synthetic personas to take your insights fur... As AI continues to reshape the healthcare landscape, pharma teams are beginning to leverage synthetic personas.